Skip to main content

#151864

Anti-Cytochrome P450 3A7 [F19P2H2]

Cat. #151864

Anti-Cytochrome P450 3A7 [F19P2H2]

Cat. #: 151864

Sub-type: Primary antibody

Unit size: 100 ug

Availability: 10-12 weeks

Target: CYP3A7- Cytochrome P450 3A7 (EC 1.14.14.1) (CYPIIIA7) (P450-HFLA)

Class: Monoclonal

Application: ELISA ; IHC ; WB

Reactivity: Human

Host: Mouse

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Ayham Alnabulsi

Institute: Vertebrate Antibodies Limited

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: Anti-Cytochrome P450 3A7 [F19P2H2]
  • Research fields: Cancer;Cell signaling and signal transduction;Metabolism;Tissue-specific biology
  • Clone: F19 P2 H2
  • Tool sub type: Primary antibody
  • Class: Monoclonal
  • Conjugation: Unconjugated
  • Strain: Balb/c
  • Reactivity: Human
  • Host: Mouse
  • Application: ELISA ; IHC ; WB
  • Description: This monoclonal antibody (MAb), when used in conjunction with the Mab specific to CYP3A5 clone F18 P3 B6, is able to differentiate between the CYP450 family 3 members: CYP3A5 and CYP3A7
  • Immunogen: Ovalbumin-conjugated synthetic peptide ESRDETVSGA (C-terminal sequence)
  • Isotype: IgG1 kappa
  • Recommended controls: IHC: formalin-fixed, paraffin-embedded prostate cancer sections. Western blot: recombinant P450 (shown below @ 0.5 pmol per lane). Negative control: Gentest Cat. No M101b.

Target Details

  • Target: CYP3A7- Cytochrome P450 3A7 (EC 1.14.14.1) (CYPIIIA7) (P450-HFLA)
  • Tissue cell line specificity: IHC: formalin-fixed, paraffin-embedded prostate cancer sections. Western blot: recombinant P450 (shown below @ 0.5 pmol per lane). Negative control: Gentest Cat. No M101b.
  • Target background: This monoclonal antibody (MAb), when used in conjunction with the Mab specific to CYP3A5 clone F18 P3 B6, is able to differentiate between the CYP450 family 3 members: CYP3A5 and CYP3A7

Applications

  • Application: ELISA ; IHC ; WB

Handling

  • Format: Liquid
  • Concentration: 0.9-1.1 mg/ml
  • Unit size: 100 ug
  • Storage buffer: PBS with 0.02% azide
  • Storage conditions: -15° C to -25° C
  • Shipping conditions: Dry ice

References

  • Zia et al. 2015. Int J Exp Pathol. 96(2):81-6. PMID: 25670065.
  • CYP3A isoforms in Ewing's sarcoma tumours: an immunohistochemical study with clinical correlation.
  • Downie et al. 2005. Clin Cancer Res. 11(20):7369-75. PMID: 16243809.
  • Profiling cytochrome P450 expression in ovarian cancer: identification of prognostic markers.
  • Kumarakulasingham et al. 2005. Clin Cancer Res. 11(10):3758-65. PMID: 15897573.
  • Cytochrome p450 profile of colorectal cancer: identification of markers of prognosis.

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.